Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases

Ann Rheum Dis. 2021 Oct;80(10):1365-1366. doi: 10.1136/annrheumdis-2021-221145. Epub 2021 Aug 24.
No abstract available

Keywords: COVID-19; antirheumatic agents; autoimmune diseases; epidemiology; vaccination.

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibody Formation
  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • Musculoskeletal Diseases*
  • SARS-CoV-2


  • COVID-19 Vaccines